| Name | Title | Contact Details |
|---|
With a history spanning more than 145 years, Columbus McKinnon has become a global leader in intelligent motion solutions. Our high-quality brands, such as CM®, STAHL CraneSystems®, Yale®, Magnetek®, Coffing® Hoists, Dorner®, and Duff-Norton®, work together to move the world forward and improve lives. Whether its increasing safety or improving productivity, our intelligent motion technology is hard at work worldwide.
Artist Partner Group (APG) is a record label and music publishing company based in Los Angeles, California. Founded in 2013 by Mike Caren, APG initially operated as a joint venture with Atlantic Records and Warner Music Group. In November 2020, it became an independent entity after Atlantic Records acquired its catalog and roster. APG focuses on music publishing and record label operations, providing a platform for artists and songwriters to create and distribute music. The company emphasizes partnership and creativity, offering concierge-level creative services to support its writers. APG has played a significant role in the careers of various notable artists, including YoungBoy Never Broke Again, Charlie Puth, and Kehlani. The parent company of APG is Artist Publishing Group, also founded by Mike Caren, with distribution managed by Warner ADA.
Fleetworx help the car fleet supply chain work better for everyone. We do this by combining data analytics with technology and expertise. Our specialist services help businesses deliver robust company car fleet management in the UK and across EMEA. We leverage data analytics to dramatically improve decision making and our expertise and practical influence spans the entire fleet supply chain. Our primary objective is to deliver savings, compliance and control and our focused and impartial approach is proven to deliver a significant return on investment. Savings - we provide client-side support in the design and delivery of cost-saving and carbon-saving company car policies. Compliance - we act as an extension of your business. Our robust Management Information System, Fleetworx Centrax, ensure you and your supply chain is fully compliant. Control - we impose tight control on all aspects of your company car fleet, creating a slick, cost-effective and valued reward and retention solution. Our services are particularly valued by fleet generalists in HR/procurement or finance roles who have company car fleet responsibility Contact us at sales@fleetworx.com or visit our website to read our thoughts on the fleet sector and learn more about how we help our clients.
SMSI is a small business providing management and technical/engineering services to the DOE/NNSA, national laboratories, and industrial clients. Our work with nuclear facility operations and safety has set the standard for excellence. We are the resource for highly technical engineering and nuclear safety basis development, review, and implementation at the national laboratories. SMSI has a demonstrated record of success providing superior people developing and implementing innovative solutions, delivering projects on time and within budget. We build productive relationships by being highly responsive to our customers. Operations began in 2000 with headquarters in Albuquerque, NM, and currently operating offices in Los Alamos, NM and Oak Ridge, TN.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.